Evidence map›Paper›PMID 40189705›Full record

ArticleOncogene2025

CDX2 downregulation regulates intrinsic WNT pathway activation, dictating metastasis in APC and CTNNB1 wildtype colorectal cancer.

Valérie M Wouters, Roxan F C P A Helderman, Kate Cameron, Sander R van der Hooff, Arezo Torang, Saskia van den Bergh, Rene Jackstadt, Owen J Sansom, Sanne M van Neerven, Jan Paul Medema

Abstract read
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valérie M WoutersLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, van der Boechorststraat 6b, 1081BT, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-4025-3531
Roxan F C P A HeldermanLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, van der Boechorststraat 6b, 1081BT, Amsterdam, The Netherlands.
Kate CameronLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, van der Boechorststraat 6b, 1081BT, Amsterdam, The Netherlands.
Sander R van der HooffLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, van der Boechorststraat 6b, 1081BT, Amsterdam, The Netherlands.
Arezo TorangLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, van der Boechorststraat 6b, 1081BT, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-7912-3964
Saskia van den BerghLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, van der Boechorststraat 6b, 1081BT, Amsterdam, The Netherlands.
Rene JackstadtHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany. Cancer Progression and Metastasis Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Owen J SansomCRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID http://orcid.org/0000-0001-9540-3010
Sanne M van NeervenWellcome Trust-Cancer Research UK Gurdon Institute, University of Cambridge, CB2 1QN, Cambridge, UK.ORCID http://orcid.org/0000-0003-2599-5756
Jan Paul MedemaLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, van der Boechorststraat 6b, 1081BT, Amsterdam, The Netherlands. j.p.medema@amsterdamumc.nl.ORCID http://orcid.org/0000-0003-3045-2924

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) can be divided into 4 subtypes of which consensus molecular subtype 4 (CMS4) is associated with metastasis and poor survival. Previously, we reported that the KPN mouse model resembles human CMS4. Strikingly, although tumor formation in this model is slow and limited, effective metastasis is observed. To understand this aggressive behavior, we compared two distinct in vitro KPN models, organoids and tumoroids. The organoid model only carries the original mutations, while the tumoroids are derived from in vivo grown tumors that underwent selection during development. Here, we reveal that tumoroids harbor endogenous WNT pathway activity, which can be driven by tankyrase activity and Cdx2 downregulation. Importantly, WNT pathway activation was heterogeneous in nature, subject to regulation and allowed for a mixture of WNT-driven and YAP-driven cells within tumoroids. This unique type of WNT pathway activation is not crucial for colonic tumor growth, but results in metastatic spreading. Intriguingly, these findings reflect a specific subset of aggressive human CMS4 cancers that display low CDX2 expression and lack of classical WNT pathway mutations, while having a higher tendency to metastasize. Together, these data propose a novel mechanism for WNT pathway activation that drives metastasis formation in aggressive CRC.

Indexed as

Adenomatous Polyposis Coli Proteinbeta CateninCDX2 Transcription FactorColorectal NeoplasmsWnt Signaling PathwayAnimalsDown-RegulationGene Expression Regulation, NeoplasticHumansMiceNeoplasm MetastasisOrganoidsAdenomatous Polyposis Coli Proteinbeta CateninCDX2 protein, humanCDX2 Transcription FactorCTNNB1 protein, human

Identifiers

PMID40189705
PMCPMC12167708

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.